William S. Velasquez

4.3k total citations
58 papers, 3.5k citations indexed

About

William S. Velasquez is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, William S. Velasquez has authored 58 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Pathology and Forensic Medicine, 24 papers in Oncology and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in William S. Velasquez's work include Lymphoma Diagnosis and Treatment (43 papers), Lung Cancer Treatments and Mutations (14 papers) and Chronic Lymphocytic Leukemia Research (13 papers). William S. Velasquez is often cited by papers focused on Lymphoma Diagnosis and Treatment (43 papers), Lung Cancer Treatments and Mutations (14 papers) and Chronic Lymphocytic Leukemia Research (13 papers). William S. Velasquez collaborates with scholars based in United States, Spain and Malaysia. William S. Velasquez's co-authors include Fredrick B. Hagemeister, Fernando Cabanillas, Peter McLaughlin, Lillian M. Fuller, F Swan, J R Redman, Maria Alma Rodriguez, Jorge Romaguera, Charles Koller and Moshe Talpaz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Internal Medicine.

In The Last Decade

William S. Velasquez

57 papers receiving 3.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
William S. Velasquez United States 29 2.5k 1.4k 1.3k 638 597 58 3.5k
F Swan United States 31 2.5k 1.0× 1.7k 1.2× 1.1k 0.8× 760 1.2× 538 0.9× 55 3.2k
B Coiffier France 18 3.7k 1.5× 2.4k 1.7× 1.4k 1.0× 1.0k 1.6× 564 0.9× 43 4.4k
Frederick Hagemeister United States 27 2.3k 0.9× 1.7k 1.2× 1.0k 0.8× 470 0.7× 603 1.0× 69 3.3k
Tak Takvorian United States 27 1.5k 0.6× 1.1k 0.8× 899 0.7× 529 0.8× 362 0.6× 58 2.9k
Andreas H. Sarris United States 30 2.4k 0.9× 1.5k 1.1× 1.0k 0.8× 488 0.8× 416 0.7× 67 3.3k
Marcel Reiser Germany 28 2.5k 1.0× 1.9k 1.4× 1.3k 1.0× 714 1.1× 519 0.9× 124 3.6k
Emilio Iannitto Italy 29 2.4k 1.0× 1.3k 0.9× 916 0.7× 679 1.1× 637 1.1× 78 3.5k
TP Miller United States 22 1.8k 0.7× 2.0k 1.5× 695 0.5× 508 0.8× 377 0.6× 28 3.3k
J L Harousseau France 22 1.8k 0.7× 1.8k 1.3× 815 0.6× 590 0.9× 291 0.5× 36 3.3k
Alessandro Pulsoni Italy 30 2.1k 0.8× 1.9k 1.4× 1.2k 0.9× 502 0.8× 327 0.5× 143 4.5k

Countries citing papers authored by William S. Velasquez

Since Specialization
Citations

This map shows the geographic impact of William S. Velasquez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William S. Velasquez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William S. Velasquez more than expected).

Fields of papers citing papers by William S. Velasquez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William S. Velasquez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William S. Velasquez. The network helps show where William S. Velasquez may publish in the future.

Co-authorship network of co-authors of William S. Velasquez

This figure shows the co-authorship network connecting the top 25 collaborators of William S. Velasquez. A scholar is included among the top collaborators of William S. Velasquez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William S. Velasquez. William S. Velasquez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Velásquez, Cristóbal Lárez, et al.. (2007). Amidación del quitosano con cloruro de oleoilo. 8(4). 229–240. 1 indexed citations
2.
Velasquez, William S., et al.. (2004). Topotecan, Ara-C, Cisplatin and Prednisolone (TOPOSHAP) for Patients with Refractory and Relapsing Lymphomas: Results of a Phase I Trial. Acta Haematologica. 112(3). 121–125. 2 indexed citations
3.
Byrd, John C., Christine A. White, Brian K. Link, et al.. (1999). Rituximab therapy in Waldenstrom's macroglobulinemia: Preliminary evidence of clinical activity. Annals of Oncology. 10(12). 1525–1527. 85 indexed citations
4.
Spitzer, Gary, Douglas Adkins, William S. Velasquez, et al.. (1997). Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy. Bone Marrow Transplantation. 20(11). 921–930. 60 indexed citations
5.
Dunphy, Cherie H., et al.. (1996). Acute myelofibrosis terminating in acute lymphoblastic leukemia: Case report and review of the literature. American Journal of Hematology. 51(1). 85–89. 12 indexed citations
6.
Swan, F, Susan L. Tucker, Herbert A. Fritsche, et al.. (1995). Risk Classification for Large Cell Lymphoma using Lactate Dehydrogenase, Beta-2 Microglobulin, and Thymidine Kinase. Leukemia & lymphoma. 18(1-2). 87–92. 18 indexed citations
7.
Rodríguez, Maritza, Fernando Cabanillas, William S. Velasquez, et al.. (1995). Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.. Journal of Clinical Oncology. 13(7). 1734–1741. 88 indexed citations
8.
Rodriguez, Maria Alma, Lillian M. Fuller, Stuart O. Zimmerman, et al.. (1993). Hodgkin's disease: Study of treatment intensities and incidences of second malignancies. Annals of Oncology. 4(2). 125–131. 63 indexed citations
9.
Velasquez, William S.. (1993). Prognostic factors in intermediate high grade lymphoma. Cancer treatment and research. 66. 37–52. 3 indexed citations
10.
Robertson, L. E., J R Redman, James J. Butler, et al.. (1991). Discordant bone marrow involvement in diffuse large-cell lymphoma: a distinct clinical-pathologic entity associated with a continuous risk of relapse.. Journal of Clinical Oncology. 9(2). 236–242. 57 indexed citations
11.
Hagemeister, Fredrick B., Lillian M. Fuller, William S. Velasquez, et al.. (1991). Two cycles of MOPP and radiotherapy: Effective treatment for stage IIIA and IIIB Hodgkin's disease. Annals of Oncology. 2(1). 25–31. 7 indexed citations
12.
Swan, F, Fernando Cabanillas, Susan L. Tucker, et al.. (1991). Prognostic Value of Serum β-2 Microglobulin in Low-Grade Lymphoma. Annals of Internal Medicine. 114(10). 855–860. 82 indexed citations
13.
Bodey, Gerald P., Alexandre Reuben, Linda S. Elting, et al.. (1991). Comparison of two schedules of cefoperazone plus aztreonam in the treatment of neutropenic patients with fever. European Journal of Clinical Microbiology & Infectious Diseases. 10(7). 551–558. 8 indexed citations
14.
Vadhan‐Raj, Saroj, William S. Velasquez, James J. Butler, et al.. (1990). Stimulation of myelopoiesis in chronic lymphocytic leukemia and in other lymphoproliferative disorders by recombinant human granulocyte‐macrophage colony‐stimulating factor. American Journal of Hematology. 33(3). 189–197. 14 indexed citations
15.
Jagannath, Sundar, Jamés O. Armitage, K. A. Dicke, et al.. (1989). Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.. Journal of Clinical Oncology. 7(2). 179–185. 172 indexed citations
16.
Swan, F, William S. Velasquez, S. C. Tucker, et al.. (1989). A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels.. Journal of Clinical Oncology. 7(10). 1518–1527. 128 indexed citations
17.
McLaughlin, Peter, Fernando Cabanillas, F. B. Hagemeister, & William S. Velasquez. (1987). Activity of bisantrene in refractory lymphoma.. PubMed. 71(6). 631–3. 4 indexed citations
18.
Cabanillas, Fernando, Fredrick B. Hagemeister, Peter McLaughlin, et al.. (1987). Results of MIME salvage regimen for recurrent or refractory lymphoma.. Journal of Clinical Oncology. 5(3). 407–412. 204 indexed citations
19.
Velasquez, William S., Lillian M. Fuller, Fredrick B. Hagemeister, et al.. (1984). Combined modality therapy in stage III and stage IIIE diffuse large cell lymphomas. Cancer. 53(7). 1478–1483. 14 indexed citations
20.
Hagemeister, F. B., et al.. (1982). Prognostic factors for stage IV Hodgkin's disease (HD) treated with MOPP. 1. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by F Swan Breakdown of academic impact, for papers by B Coiffier Breakdown of academic impact, for papers by Frederick Hagemeister Breakdown of academic impact, for papers by Tak Takvorian Breakdown of academic impact, for papers by Andreas H. Sarris Breakdown of academic impact, for papers by Marcel Reiser Breakdown of academic impact, for papers by Emilio Iannitto Breakdown of academic impact, for papers by TP Miller Breakdown of academic impact, for papers by J L Harousseau Breakdown of academic impact, for papers by Alessandro Pulsoni
Rankless by CCL
2026